Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior PLC announced a three-phase operational plan—the Indivior Action Agenda—focused on generating momentum through 2025 by growing SUBLOCADE in the U.S., simplifying the organization, and accelerating long-acting injectable penetration and SUBLOCADE net revenue thereafter. On August 26, 2025 the company began Phase 1 initiatives that include headcount reductions, real estate consolidations, and consulting, legal, and tax planning. Indivior estimates $39–$50 million of pre-tax restructuring charges (about $27–$35 million cash) to be recognized in Q3 and Q4 2025 and says it will exclude these charges from non-GAAP measures. The company is also exploring strategic alternatives for OPVEE and its non-U.S. business; further one-time costs and savings could result. Estimates are subject to change based on assumptions and execution.
Indivior PLC announced it entered into a new U.S.-style Employment Agreement and a Confidentiality, Proprietary Rights and Non-Competition Agreement with its Chief Financial Officer, Ryan Preblick, replacing his prior 2020 agreement. The company states there were no changes to his compensation, responsibilities, or title. The agreement specifies an annual base salary of $558,819, an annual cash bonus opportunity targeted at 60% of base salary (with a maximum opportunity of 120%), and potential long-term incentive awards with a grant-date value anticipated at 400% of base salary, subject to the Compensation Committee's discretion. The full agreements are filed as Exhibit 10.1 and Exhibit 10.2 and are incorporated by reference.
The filing reports that The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC jointly beneficially own 9,789,169 ordinary shares of Indivior PLC, representing approximately 7.8% of the class. The statement shows shared voting power of 9,789,144 shares and shared dispositive power of 9,789,169 shares, with no sole voting or sole dispositive power reported.
Exhibits identify the GS Group as a parent holding company and Goldman Sachs & Co. LLC as a broker-dealer and registered investment adviser. The filing includes a joint filing agreement and a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control. The statement provides ownership disclosure but does not disclose acquisition terms or strategic plans.
Q2 2025 snapshot: Net revenue rose 1% YoY to $302 m as SUBLOCADE sales grew 9% to $209 m, offsetting softer U.S. sublingual products. Gross margin expanded to 83% (74% last year) after prior-year PERSERIS exit costs rolled off. Operating income swung to $72 m from a $(118) m loss and diluted EPS reached $0.14 versus $(0.72). For the first half, revenue slipped 3% to $568 m but EPS improved to $0.52.
Cash & leverage: Operating cash flow jumped to $233 m, aided by delayed rebate payments, taking cash to $510 m and creating net cash of roughly $184 m against $326 m total debt. Capital-expenditure guidance remains $50-70 m for FY25, mainly for SUBLOCADE capacity.
Legal & tax items: Antitrust liabilities are down to an NPV of $20 m, and a $79 m provision covers opioid-MDL settlement offers. New dental-injury MDL (≈21,000 plaintiffs) and U.K. shareholder suits introduce fresh uncertainty. A £33 m HMRC reserve pushed the effective tax rate to 71%.
Strategic moves: LSE delisting completed; the company joins the Russell 2000/3000 and will lose foreign-private-issuer status in 2026. Manufacturing footprint is being consolidated; a Curia supply contract ends January 2026 without material penalties.
Management outlook: Guidance implies gross margin in the low-to-mid-80% range, SG&A/R&D below 2024, and continued double-digit SUBLOCADE growth sufficient to offset mature-product erosion. Management does not expect material impact from new U.S. tax legislation.
Indivior announced two significant board-related developments in this 8-K filing. Stuart A. (Tony) Kingsley has been appointed as a non-executive director effective July 1, 2025. His appointment aligns with the Amended and Restated Relationship Agreement with Oaktree Value Opportunities Fund and related entities.
The company also disclosed new director equity arrangements:
- Five U.S.-based non-executive directors (Keith Humphreys, Daniel Ninivaggi, Barbara Ryan, Mark Stejbach, and David Wheadon) entered into a Purchase Plan with J.P. Morgan Securities for quarterly stock purchases
- The plan allows directors to defer approximately 70-80% of their after-tax base retainer into company shares
- U.K.-based director Juliet Thompson and related party Timothy Thompson purchased 1,925 and 3,850 Ordinary Shares respectively, with company reimbursement planned over the next year
These arrangements demonstrate a strategic move to increase share ownership among non-executive directors, aligning with the 2025 Directors' Remuneration Policy approved by shareholders.